Letters to the Editor

Letter of the Week: The need for prescription drug monitoring

For Show-Me State lawmakers, making a prescription drug monitoring program a reality is a critical step to combat opioid abuse. Mallinckrodt Pharmaceuticals, along with more than 40 groups, is calling for passage of a statewide program.

Mallinckrodt is committed to providing safe and effective medications to treat patients affected by pain. The company is equally committed to working with patient groups, policymakers, law enforcement and industry to address the complex issues of opioid addiction and abuse.

Prescription drug monitoring programs help prevent drug misuse and abuse by providing prescribers timely data to guide the treatment of patients. Reducing the ability to visit numerous doctors and to obtain and fill multiple prescriptions is paramount, whether for someone struggling with addiction or individuals who are involved in illegal drug diversion and sales.

Prescription drug monitoring programs improve health outcomes, shorten the time needed to conduct law enforcement investigations and help lower abuse and diversion. As it creates a secure database, Missouri can build on best patient privacy practices.

Prescription drug monitoring programs provide a valuable tool for 49 other states; Missouri should be no exception.

Mark Trudeau of St. Louis is president and chief executive officer of Mallinckrodt Pharmaceuticals, a biopharmaceutical company with its U.S. headquarters in St. Louis.

  Comments